REDWOOD CITY, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 187,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $4.17, the closing trading price on the grant date. One Senior Vice President level executive was granted options to purchase 100,000 shares; and five additional non-officer employees were granted options to purchase an aggregate of 87,000 shares.
The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
Coherus BioSciences Contact Information:
IR Contact
Marek Ciszewski
Coherus BioSciences, Inc.
IR@coherus.com
| Last Trade: | US$0.79 |
| Daily Change: | -0.04 -4.25 |
| Daily Volume: | 2,609,786 |
| Market Cap: | US$91.020M |
May 12, 2025 March 10, 2025 January 22, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
